Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Progression of morphological changes after transplantation of a liver with heterozygous α-1 antitrypsin deficiency.

Lee SM, Speeg KV, Pollack MS, Sharkey FE.

Hum Pathol. 2012 May;43(5):753-6. doi: 10.1016/j.humpath.2011.08.001. Epub 2011 Dec 9.

PMID:
22154055
2.

High-grade microsteatosis and delay in hepatic function after orthotopic liver transplantation.

Sharkey FE, Lytvak I, Prihoda TJ, Speeg KV, Washburn WK, Halff GA.

Hum Pathol. 2011 Sep;42(9):1337-42. doi: 10.1016/j.humpath.2010.12.004. Epub 2011 Mar 21.

PMID:
21420717
3.

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.

Wang Y, Speeg KV, Washburn WK, Halff G.

World J Gastroenterol. 2010 Nov 21;16(43):5518-22.

4.

Transjugular intrahepatic portosystemic shunt for variceal hemorrhage due to recurrent of hereditary hemorrhagic telangiectasia in a liver transplant.

Cura MA, Postoak D, Speeg KV, Vasan R.

J Vasc Interv Radiol. 2010 Jan;21(1):135-9. doi: 10.1016/j.jvir.2009.09.009. Epub 2009 Nov 18.

PMID:
19926494
5.

Impact of recipient MELD score on resource utilization.

Washburn WK, Pollock BH, Nichols L, Speeg KV, Halff G.

Am J Transplant. 2006 Oct;6(10):2449-54. Epub 2006 Aug 1.

6.

Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis.

Pollack MS, Speeg KV, Callander NS, Freytes CO, Espinoza AA, Esterl RM, Abrahamian GA, Washburn WK, Halff GA.

Hum Immunol. 2005 Jan;66(1):28-31.

PMID:
15620459
7.

Liver transplantation at the University of Texas Health Science Center/University Hospital in San Antonio.

Halff G, Speeg KV, Washburn K, Esterl R, Abrahamian G, Mejia A, Nichols L, Neigut D, Dodd G, Cigarroa F.

Clin Transpl. 2003:247-53.

PMID:
15387116
8.
9.

Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score.

Ferral H, Gamboa P, Postoak DW, Albernaz VS, Young CR, Speeg KV, McMahan CA.

Radiology. 2004 Apr;231(1):231-6. Epub 2004 Feb 27.

PMID:
14990811
10.
11.

Histologic changes resembling acute rejection in a liver transplant patient treated with terbinafine.

Lovell MO, Speeg KV, Havranek RD, Sharkey FE.

Hum Pathol. 2003 Feb;34(2):187-9.

PMID:
12612888
12.

Evaluation of a model to predict poor survival in patients undergoing elective TIPS procedures.

Ferral H, Vasan R, Speeg KV, Serna S, Young C, Postoak DW, Wholey MH, McMahan CA.

J Vasc Interv Radiol. 2002 Nov;13(11):1103-8.

PMID:
12427809
13.

Transjugular intrahepatic portosystemic shunt creation in a patient with situs inversus.

Postoak DW, Ferral H, Washburn WK, Speeg KV, Wholey MH.

J Vasc Interv Radiol. 2002 Jul;13(7):755-6. No abstract available.

PMID:
12119339
14.

Outcome of liver transplantation in Hispanics versus non-Hispanics: is there a difference?

Mejia A, Halff GA, Esterl R, Cigarroa F, Speeg KV, Villarreal R, Washburn K.

Transplant Proc. 2002 Jun;34(4):1236-8. No abstract available.

PMID:
12072326
15.

Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.

Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G.

Transplantation. 2001 Nov 27;72(10):1675-9.

PMID:
11726831
16.

The effects of food restriction in man on hepatic metabolism of acetaminophen.

Schenker S, Speeg KV Jr, Perez A, Finch J.

Clin Nutr. 2001 Apr;20(2):145-50.

PMID:
11327742
17.
18.

Gallbladder carcinoma producing alpha-fetoprotein.

St Laurent M, Esterl RM Jr, Halff GA, Speeg KV.

J Clin Gastroenterol. 1999 Mar;28(2):155-8.

PMID:
10078826
19.

Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation.

Cai TH, Esterl RM Jr, Nichols L, Cigarroa F, Speeg KV, Halff GA.

Transplant Proc. 1998 Jun;30(4):1413-4. No abstract available.

PMID:
9636572
20.

In-111 WBC scan localizes infected hepatic cysts and confirms their complete resection in adult polycystic kidney disease.

Lahiri SA, Halff GA, Speeg KV, Esterl RM Jr.

Clin Nucl Med. 1998 Jan;23(1):33-4. No abstract available.

PMID:
9442963
21.

Transforming growth factor alpha distribution in rectal crypts as a biomarker of decreased colon cancer risk in patients consuming cellulose.

Hardman WE, Cameron IL, Beer WH, Speeg KV, Kadakia SC, Lang KA.

Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):633-7.

22.

Endoscopic biliary stent migration with small bowel perforation in a liver transplant recipient.

Esterl RM Jr, St Laurent M, Bay MK, Speeg KV, Halff GA.

J Clin Gastroenterol. 1997 Mar;24(2):106-10.

PMID:
9077729
23.

Prevention and treatment of drug-induced liver disease.

Speeg KV, Bay MK.

Gastroenterol Clin North Am. 1995 Dec;24(4):1047-64. Review.

PMID:
8749911
24.
25.

Effect of cyclosporine on colchicine partitioning in the rat liver.

Speeg KV, Maldonado AL.

Cancer Chemother Pharmacol. 1993;32(6):434-6.

PMID:
8258190
26.
27.

Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo.

Speeg KV, Maldonado AL, Liaci J, Muirhead D.

Hepatology. 1992 May;15(5):899-903.

PMID:
1568732
28.

Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo.

Speeg KV, Maldonado AL, Liaci J, Muirhead D.

J Pharmacol Exp Ther. 1992 Apr;261(1):50-5.

PMID:
1348538
29.

Colchicine clearance is impaired in alcoholic cirrhosis.

Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV.

Hepatology. 1991 Dec;14(6):1013-5.

PMID:
1959847
30.

Isolation and characterization of an adriamycin-resistant breast tumor cell line.

Schneider SL, Fuqua SA, Speeg KV, Tandon AK, McGuire WL.

In Vitro Cell Dev Biol. 1990 Jun;26(6):621-8.

PMID:
1972704
31.

The effect of liver dysfunction on colchicine pharmacokinetics in the rat.

Leighton JA, Bay MK, Maldonado AL, Johnson RF, Schenker S, Speeg KV.

Hepatology. 1990 Feb;11(2):210-5.

PMID:
2307399
32.

The risk of alcohol intake in men and women: all may not be equal.

Schenker S, Speeg KV.

N Engl J Med. 1990 Jan 11;322(2):127-9. No abstract available.

PMID:
2403653
33.

Toxic delirium in a patient taking amantadine and trimethoprim-sulfamethoxazole.

Speeg KV, Leighton JA, Maldonado AL.

Am J Med Sci. 1989 Dec;298(6):410-2.

PMID:
2596498
34.

The effect of route of administration on the cimetidine-theophylline drug interaction.

Cremer KF, Secor J, Speeg KV Jr.

J Clin Pharmacol. 1989 May;29(5):451-6.

PMID:
2738177
35.

Organic cation uptake by a cultured renal epithelium.

McKinney TD, DeLeon C, Speeg KV Jr.

J Cell Physiol. 1988 Dec;137(3):513-20.

PMID:
3192630
36.

Effect of aging on hepatic elimination of cimetidine and subsequent interaction of aging and cimetidine on aminopyrine metabolism.

Henderson GI, Speeg KV Jr, Roberts RK, Perez A, Schenker S.

Biochem Pharmacol. 1988 Jul 1;37(13):2667-73.

PMID:
3390226
37.

Potential use of cimetidine for treatment of acetaminophen overdose.

Speeg KV.

Pharmacotherapy. 1987;7(6 Pt 2):125S-133S. Review.

PMID:
3328168
38.

Hepatic oxidative drug metabolism and the microsomal milieu in a rat model of congenital hyperbilirubinemia.

Meredith CG, Muhoberac BB, Gray JP, Speeg KV Jr, Dunn D, Hoyumpa AM, Schenker S.

Biochem Pharmacol. 1986 Nov 1;35(21):3831-7.

PMID:
3778508
39.

Effect of H2-receptor antagonists on steady-state extraction of indocyanine green and lidocaine by the perfused rat liver.

Roberts RK, Heath CA, Johnson RF, Speeg KV Jr, Schenker S.

J Lab Clin Med. 1986 Feb;107(2):112-7.

PMID:
2868064
40.

Lack of effect of nizatidine on hepatic drug metabolism in man.

Secor JW, Speeg KV Jr, Meredith CG, Johnson RF, Snowdy P, Schenker S.

Br J Clin Pharmacol. 1985 Dec;20(6):710-3.

41.

Additive protection of cimetidine and N-acetylcysteine treatment against acetaminophen-induced hepatic necrosis in the rat.

Speeg KV Jr, Mitchell MC, Maldonado AL.

J Pharmacol Exp Ther. 1985 Sep;234(3):550-4.

PMID:
4032281
42.

The effect of cimetidine on hepatic drug elimination in cirrhosis.

Nelson DC, Avant GR, Speeg KV Jr, Hoyumpa AM Jr, Schenker S.

Hepatology. 1985 Mar-Apr;5(2):305-9.

PMID:
3979962
43.

Effect of ketoconazole on hepatic oxidative drug metabolism.

Brown MW, Maldonado AL, Meredith CG, Speeg KV Jr.

Clin Pharmacol Ther. 1985 Mar;37(3):290-7.

PMID:
3971653
44.

The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro.

Meredith CG, Maldonado AL, Speeg KV Jr.

Drug Metab Dispos. 1985 Mar-Apr;13(2):156-62.

PMID:
2859162
45.
46.

Cimetidine inhibits renal procainamide clearance.

Christian CD Jr, Meredith CG, Speeg KV Jr.

Clin Pharmacol Ther. 1984 Aug;36(2):221-7.

PMID:
6204803
47.

Ranitidine and acetaminophen hepatotoxicity.

Speeg KV Jr, Christian DC, Mitchell MC.

Ann Intern Med. 1984 Feb;100(2):315-6. No abstract available.

PMID:
6318636
49.

Phosphotyrosyl-protein phosphatase of TCRC-2 cells.

Swarup G, Speeg KV Jr, Cohen S, Garbers DL.

J Biol Chem. 1982 Jul 10;257(13):7298-301.

50.

Cimetidine and procainamide secretion by proximal tubules in vitro.

McKinney TD, Speeg KV Jr.

Am J Physiol. 1982 Jun;242(6):F672-80.

PMID:
6178296

Supplemental Content

Loading ...
Support Center